| Date | Title | Description |
| 13.08.2026 | Tenosynovial Giant Cell Tumor Treatment Market to Witness Robust Growth Driven by Precision Medicine and Targeted Oncology Innovation | Overview
According to DataM Intelligence, the global tenosynovial giant cell tumor treatment market size reached USD 8.88 billion in 2025 and is forecast to reach USD 13.40 billion by 2035, expanding at a CAGR of 4.2% during the 2026–2035 f... |
| 07.04.2026 | The End Brain Cancer Initiative Releases Free Educational Videos Featuring New Developments in PCNSL Treatment | Free patient disease education videos from the End Brain Cancer Initiative's “New Developments in PCNSL Treatment” educational webinar are now available. REDMOND, WA, UNITED STATES, April 7, 2026 /EINPresswire.com/ -- On Friday, March 27th,... |
| 23.03.2026 | The End Brain Cancer Initiative is Hosting a Free Webinar Featuring the Latest Advances in PCNSL Treatment on March 27 | Join the “New Developments in PCNSL Treatment” webinar to learn about new research, clinical trials, specialists, treatments, diagnostics, and support. REDMOND, WA, UNITED STATES, March 23, 2026 /EINPresswire.com/ -- On Friday, March 27th a... |
| 19.05.2025 | J.P. Morgan Life Sciences Private Capital Adds Dashyant Dhanak, Ph.D. as Venture Partner | Dashyant (Dash) Dhanak, Ph.D.
J.P. Morgan Life Sciences Private Capital, the NYC-based life sciences venture and growth equity arm within J.P. Morgan Asset Management, announced the appointment of Dashyant Dhanak, Ph.D., as Venture Partner.... |
| 11.06.2024 | Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) | OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April ... |
| 11.06.2024 | Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) | OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April ... |
| 29.04.2024 | Former SV Portfolio Company Deciphera acquired by Ono Pharmaceutical for $2.4B after biotech's Phase 3 win | Japanese drugmaker Ono Pharmaceutical is acquiring cancer-focused biotech Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday morning. |
| 17.09.2021 | Deciphera Pharmaceuticals : Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor (Form 8-K) | Deciphera Announces Positive CHMP Opinion for QINLOCK®for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
- European Commission Decision Anticipated by the Fourth Quarter of 2021 -
Waltham, MA - September 17, 2021 - Deciphera Ph... |
| 23.11.2020 | The Boston Globe Names Deciphera a Top Place to Work for 2020 | WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the Top Places t... |
| 22.06.2020 | Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor | June 22, 2020 at 7:00 AM EDTPDF Version |
| 08.06.2020 | Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology | June 8, 2020 at 7:30 AM EDTPDF Version |
| 29.05.2020 | Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ... | Patients Receiving QINLOCK for Fourth-line GIST Reported Improved Quality of Life and Better Physical and Role Functioning Compared with a Decline in Placebo- |
| 16.12.2019 | Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors | – Application is Being Reviewed Under FDA’s Real-Time Oncology Review (RTOR) Pilot Program – |
| 28.10.2019 | FDA to split Blueprint’s cancer drug application in two | Shares of Blueprint were down about 5 percent on the NASDAQ Monday morning following the news. GIST is a sarcoma, meaning a cancer of the connective tissue. Avapritinib is an inhibitor of KIT and PDGFRa that is also in development for advan... |
| 28.09.2017 | Term Sheet — Thursday, September 28 | DIAL UP THE DRAMA
Good morning, Term Sheet readers!
Paid Content You can't secure what you can't see From ExtraHop
BITCOIN SOUND OFF: The Wolf of Wall Street has spoken. Jordan Belfort, the former stockbroker who pled guilty to fraud, calle... |
| 19.09.2017 | Term Sheet — Tuesday, September 19 | VCs VERSUS ICOs
Companies have raised more than $1.7 billion through initial coin offerings this year, surpassing early-stage VC funding for Internet companies. It’s easy to see why an ICO is appealing to tech founders (No due diligence! LO... |
| 05.09.2017 | Term Sheet — Tuesday, September 5 | CATCH UP
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
SQUEEZED OUT: On Friday, we bid farewell to Juicero, our favorite juicer company to make fun of on Twitter. After raising... |
| 10.07.2017 | Chemotherapy before breast cancer surgery might fuel metastasis | When breast cancer patients get chemotherapy before surgery to remove their tumor, it can make remaining malignant cells spread to distant sites, resulting in incurable metastatic cancer, scientists reported last week.
The main goal of pre-... |
| 01.06.2017 | Deciphera Pharmaceuticals Raises $52M in Series C Financing | Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, closed a $52m Series C financing.
The round was led by Viking Global Investors LP, Redmil... |
| 01.06.2017 | Deciphera Pharmaceuticals Snags $52M |
WALTHAM, MA, Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it closed a $52 million Series C.
>> Click here for more funding... |
| 01.06.2017 | Deciphera Pharmaceuticals Raises $52 Million Series C | WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it closed a $52 million Series C financing led by Vik... |
| 03.11.2016 | The top 15 healthcare deals of 2016 | There has been $13.1 billion invested across 1,287 deals so far this year
Even as venture funding has slowed down this year, healthcare has remained one of the top spaces for companies to raise money.
In the first quarter of this year, even... |
| 06.01.2016 | Deciphera Pharmaceuticals Increases Size of Series B Round to over $90M | Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments, has increased the size of its Series B financing to over $90m.
SV Life Sciences made the additio... |
| 05.01.2016 | Daily funding roundup - January 5, 2016 | PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M
Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me... |
| 21.09.2015 | Daily funding roundup - September 21, 2015 | Deciphera bagged $75M; Portea raised $37.5M; Just Biotherapeutics secured $15M
BidFlyer, an Israeli startup that is a white-label platform for airlines, has raised $1 million in funding for its business model, which involves putting small b... |
| 21.09.2015 | Deciphera Pharmaceuticals Nets $75M Series B |
WALTHAM, MA, Clinical-stage biotechnology company has closed a $75 million Series B financing.
>> Click here for more funding data on Deciphera Pharmaceuticals
>> To export Deciphera Pharmaceuticals funding data to PDF and E... |
| 21.09.2015 | Kinase-focused Deciphera gets marquee backing for a big $75M venture round | A little more than a year after Deciphera CEO Mike Taylor set up an office for the biotech in the Boston area, the cancer drug developer has rounded up a whopping $75 million B round to make a clinical push for its top cancer drug candidate... |
| 21.09.2015 | Deciphera raises $75M directed toward kinase-inhibiting cancer drug | Taylor aims to eventually put together a broad syndicate of crossover investors that can support an IPO, but the $75 million, which should fund Deciphera through 2017, gives the company some time to decide when. It’ll gather clinical data o... |
| 21.09.2015 | Deciphera Pharmaceuticals Closes $75M Series B Financing | Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, closed a $75m Series B financing.
The ro... |
| - | Deciphera raises $75M directed toward kinase-inhibiting cancer drug | Waltham, Massachusetts-based Deciphera has now raised $75 million with funding led by New Leaf Ventures, which was joined by the company’s lone major longtime backer, an unnamed “high net worth” investor, according to Xconomy. The funding w... |
| - | FDA to split Blueprint’s cancer drug application in two | The Food and Drug Administration will review a biotech company’s approval application for a cancer drug in two parts.
Cambridge, Massachusetts-based Blueprint Medicines said Monday that the FDA would split its application for the drug avapr... |
